Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Straumann Holding AGXSWX:STMN -0.08%94 Capex-to-Operating-Cash-Flow is 0.31 as of Jun. 2026, which is 14% below its 10-year median of 0.36. GuruFocus rates XSWX:STMN with a GF Score™ of 94/100 and a GF Value™ of CHF126.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 444 Medical Devices & Instruments companies, Straumann Holding AG ranks better than 56.76% on this metric.
Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.
Straumann Holding AG (XSWX:STMN) Capex-to-Operating-Cash-Flow Explanation
Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.
Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.
Straumann Holding AG Capex-to-Operating-Cash-Flow Related Terms
Straumann Holding AG Capex-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Straumann Holding AG's Capex-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Straumann Holding AG Capex-to-Operating-Cash-Flow Chart
XSWX:STMN vs ISRG, BDX, RMD: Capex-to-Operating-Cash-Flow Comparison
For the Medical Instruments & Supplies subindustry, Straumann Holding AG's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Straumann Holding AG Capex-to-Operating-Cash-Flow vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Straumann Holding AG's Capex-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Straumann Holding AG's Capex-to-Operating-Cash-Flow falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Capex-to-Operating-Cash-Flow of 0.31 mean?
Straumann Holding AG (XSWX:STMN) has a Capex-to-Operating-Cash-Flow of 0.31 as of Jun. 2026. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Straumann Holding AG and its competitors. This is 14% below median its historical median of 0.36. Over the past decade, Straumann Holding AG's Capex-to-Operating-Cash-Flow has ranged from 0.22 to 0.47. According to the industry distribution chart, Straumann Holding AG ranks #192 out of 444 companies in the Medical Devices & Instruments industry, placing it in the top 43.2%.
Is Straumann Holding AG's Capex-to-Operating-Cash-Flow too high?
Straumann Holding AG's current Capex-to-Operating-Cash-Flow of 0.31 is 14% below median its 10-year median of 0.36. Over the past 10 years, this metric has ranged from a low of 0.22 to a high of 0.47. The Medical Devices & Instruments industry median Capex-to-Operating-Cash-Flow is 0.41. Straumann Holding AG's value of 0.31 is 24.4% below this industry median. Based on the distribution chart, Straumann Holding AG ranks #192 out of 444 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Straumann Holding AG has a GF Score™ of 94/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Straumann Holding AG's Capex-to-Operating-Cash-Flow compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Straumann Holding AG ranks #192 out of 444 companies for Capex-to-Operating-Cash-Flow. This puts Straumann Holding AG in the upper half of its industry. The industry median Capex-to-Operating-Cash-Flow is 0.41. Straumann Holding AG's value of 0.31 is 24.4% below this benchmark. Historically, Straumann Holding AG's own Capex-to-Operating-Cash-Flow has ranged from 0.22 to 0.47 over the past decade. While the company's 10-year median is 0.36 vs. the industry median of 0.41, Straumann Holding AG has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Operating-Cash-Flow for a Medical Devices & Instruments company?
The median Capex-to-Operating-Cash-Flow among Medical Devices & Instruments companies is 0.41, based on 444 companies in the industry. Companies in the top quartile (top 25%) have a Capex-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Capex-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Straumann Holding AG's current Capex-to-Operating-Cash-Flow of 0.31 is 24.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Operating-Cash-Flow mean?
A high Capex-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Capex to Operating Cash Flow ratio assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. View historical data on Straumann Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Capex-to-Operating-Cash-Flow is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Straumann Holding AG's current Capex-to-Operating-Cash-Flow is 0.31, which is 14% below median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Straumann Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Straumann Holding AG (XSWX:STMN) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF126.50, compared to a current price of CHF94.58 — trading 25.2% below its estimated fair value. The current Capex-to-Operating-Cash-Flow is 0.31, which is 14% below median its 10-year median of 0.36 and 24.4% below the Medical Devices & Instruments industry median of 0.41. Straumann Holding AG's overall GF Score™ is 94/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Operating-Cash-Flow calculated?
Capex-to-Operating-Cash-Flow is calculated from a company's financial statements. For Straumann Holding AG (XSWX:STMN), the current Capex-to-Operating-Cash-Flow is 0.31 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Straumann Holding AG (XSWX:STMN) Overvalued in 2026?
Based on GuruFocus' analysis, Straumann Holding AG stock appears to be undervalued.
The current stock price of CHF94.58 is trading 25.2% below its estimated GF Value™ of CHF126.50.
GuruFocus considers Straumann Holding AG to be Modestly Undervalued.
Key valuation signals for XSWX:STMN:
Capex-to-Operating-Cash-Flow: 0.31 (14% below median its 10-year median of 0.36)
GF Value™: CHF126.50 vs. price of CHF94.58 (25.2% below fair value)
Industry Position: 24.4% below the Medical Devices & Instruments median (#192 of 444)
No single metric tells the full story. See the XSWX:STMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Straumann is a global leader in tooth replacement and orthodontics solutions. Its line of products includes dental implants, abutments, clear aligners, biomaterials, and computer-aided design/computer-aided manufacturing equipment. The firm's core products are dental implants, and it holds over one third of the CHF 6 billion global market. Originally a pure premium implant player, Straumann entered the value market in 2012 with its acquisition of Neodent. Straumann now accounts for almost half of the global premium market and around 15% of the value market. While its premium product catalog is marketed under Straumann, its value brands include Neodent, Anthogyr, and Medentika as well as other local and regional brands.
94GF Score
Get the complete analysis for XSWX:STMN
Capex-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:STMN has been successfully added to your 
